Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

289 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Prevalence of prurigo nodularis in the United States.
Kwatra SG, Puelles J, Tran O, Brouillette M, Lillehaugen T, Parthasarathy V, Deng J, Piketty C, Gabriel S. Kwatra SG, et al. JAAD Int. 2024 Mar 22;18:134-136. doi: 10.1016/j.jdin.2023.12.013. eCollection 2025 Feb. JAAD Int. 2024. PMID: 39719959 Free PMC article. No abstract available.
Patient Perspectives on Living With Severe Prurigo Nodularis.
Rodriguez D, Kwatra SG, Dias-Barbosa C, Zeng F, Jabbar Lopez ZK, Piketty C, Puelles J. Rodriguez D, et al. Among authors: kwatra sg. JAMA Dermatol. 2023 Nov 1;159(11):1205-1212. doi: 10.1001/jamadermatol.2023.3251. JAMA Dermatol. 2023. PMID: 37728897 Free PMC article.
Phase 3 Trial of Nemolizumab in Patients with Prurigo Nodularis.
Kwatra SG, Yosipovitch G, Legat FJ, Reich A, Paul C, Simon D, Naldi L, Lynde C, De Bruin-Weller MS, Nahm WK, Sauder M, Gharib R, Barbarot S, Szepietowski JC, Conrad C, Fleischer A, Laquer VT, Misery L, Serra-Baldrich E, Lapeere H, Ahmad F, Jabbar Lopez ZK, Piketty C, Ständer S; OLYMPIA 2 Investigators. Kwatra SG, et al. N Engl J Med. 2023 Oct 26;389(17):1579-1589. doi: 10.1056/NEJMoa2301333. N Engl J Med. 2023. PMID: 37888917 Clinical Trial.
Efficacy and Safety of Nemolizumab in Patients With Moderate to Severe Prurigo Nodularis: The OLYMPIA 1 Randomized Clinical Phase 3 Trial.
Ständer S, Yosipovitch G, Legat FJ, Reich A, Paul C, Simon D, Naldi L, Metz M, Tsianakas A, Pink A, Fage S, Micali G, Weisshaar E, Sundaram H, Metelitsa A, Augustin M, Wollenberg A, Homey B, Fargnoli MC, Sofen H, Korman NJ, Skov L, Chen X, Jabbar-Lopez ZK, Piketty C, Kwatra SG; OLYMPIA 1 Investigators. Ständer S, et al. Among authors: kwatra sg. JAMA Dermatol. 2024 Nov 27. doi: 10.1001/jamadermatol.2024.4796. Online ahead of print. JAMA Dermatol. 2024. PMID: 39602139
Dupilumab improves pruritus and skin lesions in patients with prurigo nodularis: Pooled results from 2 phase 3 trials (LIBERTY-PN PRIME and PRIME2).
Yosipovitch G, Kim BS, Kwatra SG, Mollanazar NK, Ständer S, Satoh T, Mendes-Bastos P, Tsai TF, Laws E, Nivens MC, Maloney J, Shi G, Bansal A, Dubost-Brama A. Yosipovitch G, et al. Among authors: kwatra sg. JAAD Int. 2024 Apr 10;16:163-174. doi: 10.1016/j.jdin.2024.03.025. eCollection 2024 Sep. JAAD Int. 2024. PMID: 39006917 Free PMC article.
289 results